MediciNova Inc (MNOV) News Headlines

▮ More

Date

Headline

6/21/2021 6:53:26 AM MediciNova Reports Positive Results In Phase 2 Trial Of MN-166 In Alcohol Use Disorder - Quick Facts

6/21/2021 6:35:33 AM MediciNova Announces Positive Results From Phase 2 Trial Of MN-166 In Alcohol Use Disorder

3/9/2021 5:42:22 PM MediciNova Partners With BARDA To Develop Chlorine Gas-induced Lung Injury Treatment; Stock Surges

3/4/2021 2:21:01 AM KMPH Scores FDA Nod For ADHD Drug, MNOV Quits COVID-19 Vaccine Race, UTHR Gives Up On Trevyent

12/29/2020 6:43:35 AM MediciNova Receives New Patent Covering MN-166 For Treatment Of Progressive Multiple Sclerosis

12/29/2020 6:31:33 AM MediciNova Receives Notice Of Allowance For New Patent Covering MN-166

11/25/2020 6:33:11 AM MediciNova Announces Positive Optical Coherence Tomography Results From SPRINT-MS Phase 2b Trial Of MN-166

10/21/2020 6:34:19 AM MediciNova Appoints Carolyn Beaver To Its Board

9/24/2020 6:34:39 AM MediciNova: Positive Clinical Findings Published In Cancer Chemotherapy And Pharmacology On MN-166

9/23/2020 10:29:30 AM Stock Alert: MediciNova Gains 11% On Positive Covid-19 Vaccine Data

9/23/2020 9:26:17 AM MediciNova' COVID-19 Vaccine Induces Systemic Serum IgG, Mucosal IgA Neutralizing Antibodies In Mice

9/23/2020 6:45:58 AM MediciNova Says Intranasal BC-PIV SARS-CoV-2 Vaccine Induced Systemic IgG & Mucosal IgA Neutralizing Antibodies In Mice

9/23/2020 6:45:13 AM MediciNova: Intranasal BC-PIV SARS-CoV-2 Vaccine Induced Systemic IgG And Mucosal IgA Neutralizing Antibodies In Mice

9/11/2020 6:38:58 AM BioComo: Intranasal RS Virus Vaccine Induced Neutralizing Antibodies Against RS Virus In Mice Using BC-PIV Technology

7/28/2020 6:35:09 AM Pre-market Movers In Healthcare Sector: SPPI, MEDS, OCGN, SRNE, CRMD...

7/28/2020 3:06:03 AM MRNA, PFE/BNTX COVID-19 Vaccines Move Into Phase 3, CytoDyn On Watch, GNCA To Report Data On Jul.30

7/27/2020 10:25:11 AM Stock Alert: MediciNova Jumps 25%

7/27/2020 7:35:14 AM MediciNova Granted Rights To Use BC-PIV For SARS-CoV-2 Vaccine Joint Development

7/27/2020 6:53:12 AM MediciNova Enters Agreement With BioComo, Mie University For Joint Development Of SARS-CoV-2 Vaccine

7/1/2020 6:44:50 AM MediciNova Says IND For MN-166 For Prevention Of Acute Respiratory Distress Syndrome Accepted And Is Now Open With FDA

Medicinova Inc (MNOV)